// App-Quantinova.ai

: Prognostic and predictive role of CTCs and AR-V7+ CTCs expression in metastatic catrate resistant prostate cancer (mCRPC): A feasibility study.

Researchers

Presenter

  • Marco Maruzzo

Principal Investigators

  • Elisabetta Rossi

  • Umberto Basso

  • Antonella Facchinetti

  • Giuseppe Anile

  • Francesco Pierantoni

  • Sara Galuppo

  • Laura Evangelista

  • Enrico Pizzirani

  • Rita Zamarchi

  • Vittorina Zagonel

Medical Centers

  • U.O. Oncologia Medica 2, Istituto Oncologico Veneto - IRCCS, Padova, Italy

  • U.O.C. Immunologia e Diagnostica Molecolare - Oncologica Istituto Oncologico Veneto - IRCCS, Padua, Italy

  • Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

  • Medical Oncology 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

  • Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved